|
1
|
Flowers CR, Sinha R and Vose JM: Improving
outcomes for patients with diffuse large B-cell lymphoma. CA Cancer
J Clin. 60:393–408. 2010.PubMed/NCBI
|
|
2
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfreundschuh M, Trümper L, Osterborg A,
Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani
PL, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: A randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson WH, Dunleavy K, Pittaluga S, Hegde
U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA,
Staudt L, et al: Phase II study of dose-adjusted EPOCH and
rituximab in untreated diffuse large B-cell lymphoma with analysis
of germinal center and post-germinal center biomarkers. J Clin
Oncol. 26:2717–2724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gisselbrecht C, Glass B, Mounier N, Gill D
Singh, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O,
Hagberg H, et al: Salvage regimens with autologous transplantation
for relapsed large B-cell lymphoma in the rituximab era. J Clin
Oncol. 28:4184–4190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu K, Weisenburger DD, Choi WW, Perry KD,
Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, et al:
Addition of rituximab to standard chemotherapy improves the
survival of both the germinal center b-cell-like and non-germinal
center b-cell-like subtypes of diffuse large b-cell lymphoma. J
Clin Oncol. 26:4587–4594. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larouche JF, Berger F, Chassagne-Clément
C, Ffrench M, Callet-Bauchu E, Sebban C, Ghesquières H,
Broussais-Guillaumot F, Salles G and Coiffier B: Lymphoma
recurrence 5 years or later following diffuse large B-cell
lymphoma: Clinical characteristics and outcome. J Clin Oncol.
28:2094–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang C, Xu W and Li JY: A systematic
review and meta-analysis of rituximab-based immunotherapy for
subtypes of diffuse large B cell lymphoma. Ann Hematol.
89:1107–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hui D, Proctor B, Donaldson J, Shenkier T,
Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM
and Sehn LH: Prognostic implications of extranodal involvement in
patients with diffuse large B-cell lymphoma treated with rituximab
and cyclophosphamide, doxorubicin, vincristine, and prednisone.
Leuk Lymphoma. 51:1658–1667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pfreundschuh M, Trümper L, Kloess M,
Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK,
Eimermacher H, et al: Two weekly or 3-weekly CHOP chemotherapy with
or without etoposide for the treatment of elderly patients with
aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL.
Blood. 104:634–641. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cunningham D, Hawkes EA, Jack A, Qian W,
Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A,
et al: Rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisolone in patients with newly diagnosed diffuse large
B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose
intensification with 14-day versus 21-day cycles. Lancet.
381:1817–1826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Delarue R, Tilly H, Mounier N, Petrella T,
Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M,
Fruchart C, et al: Dose-dense rituximab-CHOP compared with standard
rituximab-CHOP in elderly patients with diffuse large B-cell
lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet
Oncol. 14:525–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morschhauser F, Radford J, Van Hoof A,
Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F,
Diaz M Gonzalez, et al: Phase III trial of consolidation therapy
with yttrium-90-ibritumomab tiuxetan compared with no additional
therapy after first remission in advanced follicular lymphoma. J
Clin Oncol. 26:5156–5164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Witzig TE, Gordon LI, Cabanillas F,
Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL,
Wiseman GA, Padre N, et al: Randomized controlled trial of
yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus
rituximab immunotherapy for patients with relapsed or refractory
low-grade, follicular, or transformed B-cell non-Hodgkin's
lymphoma. J Clin Oncol. 20:2453–2463. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morschhauser F, Illidge T, Huglo D,
Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied
N, Hess G, et al: Efficacy and safety of yttrium-90 ibritumomab
tiuxetan in patients with relapsed or refractory diffuse large
B-cell lymphoma not appropriate for autologous stem-cell
transplantation. Blood. 110:54–58. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Witzig TE, Molina A, Gordon LI,
Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K
and Wiseman GA: Long-term responses in patients with recurring or
refractory B-cell non-Hodgkin lymphoma treated with yttrium 90
ibritumomab tiuxetan. Cancer. 109:1804–1810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zinzani PL, Tani M, Fanti S, Stefoni V,
Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini
C, et al: A phase II trial of CHOP chemotherapy followed by yttrium
90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly
diffuse large B-cell lymphoma patients. Ann Oncol. 19:769–773.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zinzani PL, Rossi G, Franceschetti S,
Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A,
Fanti S, et al: Phase II trial of short-course R-CHOP followed by
90Y-ibritumomab tiuxetan in previously untreated high-risk elderly
diffuse large B-cell lymphoma patients. Clin Cancer Res.
16:3998–4004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheson BD, Horning SJ, Coiffier B, Shipp
MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A,
Hagenbeek A, et al: Report of an international workshop to
standardize response criteria for non-Hodgkin's lymphomas. NCI
Sponsored International Working Group. J Clin Oncol. 17:12441999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simon R: Optimal two-stage designs for
phase II clinical trials. Control Clin Trials. 10:1–10. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalbfleisch JD and Prentice RL: The
Statistical Analysis of Failure Time Data. New York: John Wiley
& Sons, Inc., 1980. Canadian Journal of Statistics. 10:64–66.
1982. View
Article : Google Scholar
|
|
23
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised International Prognostic Index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feugier P, Van Hoof A, Sebban C,
Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E,
Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP
study in the treatment of elderly patients with diffuse large
B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pfreundschuh M, Schubert J, Ziepert M,
Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M,
Peter N, et al: Six versus eight cycles of bi-weekly CHOP-14 with
or without rituximab in elderly patients with aggressive CD20+
B-cell lymphomas: A randomized controlled trial (RICOVER-60).
Lancet Oncol. 9:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Récher C, Coiffier B, Haioun C, Molina TJ,
Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G,
Morschhauser F, et al: Intensified chemotherapy with ACVBP plus
rituximab versus standard CHOP plus rituximab for the treatment of
diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised
phase 3 trial. Lancet. 378:1858–1867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stiff PJ, Unger JM, Cook JR, Constine LS,
Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, et al:
Autologous transplantation as consolidation for aggressive
non-hodgkin's lymphoma. N Engl J Med. 369:1681–1690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamlin P, Rodriguez MA, Noy A, Portlock
CS, Straus D, McLaughlin P, Pro P, Fayad L, Hagemeister F, Wegner
B, et al: Final Results of a Phase II Study of Sequential R-CHOP
and Yttrium-90 Ibritumomab Tiuxetan (RIT) For Elderly High Risk
Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).
Blood. 116:17932010.
|
|
29
|
Yang DH, Kim WS, Suh C, Kwak JY, Jung JS,
Kim SH, Kim JS, Lee JJ and Kim HJ: Phase II trial of
90Y-ibritumomab tiuxetan treatment as consolidation after 6th
R-CHOP chemotherapy in patients with limited-stage, bulky diffuse
large B-cell lymphoma. Blood. 114:37512009.
|
|
30
|
Kraeber-Bodere F, Maisonneuve H, Lamy T,
Gouill SL, Deconninck E, Pallardy A, bodet-Milin C, Milpied N,
Morineau N, Foussard C, et al: Consolidation anti-CD22 fractionated
radioimmunotherapy with 90Y epratuzumab tetraxetan following R-CHOP
in elderly DLBCL patients. Blood. 116:28752010.PubMed/NCBI
|
|
31
|
Friedberg JS, Unger JM, Burack WR, et al:
R-CHOP with iodine-131 tositumomab consolidation for advanced stage
diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol.
116:382–389. 2014. View Article : Google Scholar
|
|
32
|
Larouche JF, Berger F, Chassagne-Clément
C, Ffrench M, Callet-Bauchu E, Sebban C, Ghesquières H,
Broussais-Guillaumot F, Salles G and Coiffier B: Lymphoma
recurrence 5 years or later following diffuse large B-cell
lymphoma: Clinical characteristics and outcome. J Clin Oncol.
28:2094–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nowakowski GS, LaPlant B, Macon WR, Reeder
CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ,
Micallef IN, et al: Lenalidomide combined with R-CHOP overcomes
negative prognostic impact of non-germinal center B-cell phenotype
in newly diagnosed diffuse large B-cell lymphoma: A phase II study.
J Clin Oncol. 33:251–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Younes A, Thieblemont C, Morschhauser F,
Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J,
Bandyopadhyay N, et al: Combination of ibrutinib with rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)
for treatment-naive patients with CD20-positive B-cell non-Hodgkin
lymphoma: A non-randomised, phase 1b study. Lancet Oncol.
15:1019–1026. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Czuczman MS, Emmanouilides C, Darif M,
Witzig TE, Gordon LI, Revell S, Vo K and Molina A:
Treatment-related myelodysplastic syndrome and acute myelogenous
leukemia in patients treated with ibritumomab tiuxetan
radioimmunotherapy. J Clin Oncol. 25:4285–4292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Boehme V, Schmitz N, Zeynalova S, Loeffler
M and Pfreundschuh M: CNS events in elderly patients with
aggressive lymphoma treated with modern chemotherapy (CHOP-14) with
or without rituximab: An analysis of patients treated in the
RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma
Study Group (DSHNHL). Blood. 113:3896–3902. 2009. View Article : Google Scholar : PubMed/NCBI
|
